Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines ...

As a result, Organon was likely not on track to achieve the $1 billion milestone payment from Merck & Co. on its Nexplanon sales. On May 1, 2025, investors learned the truth when Organon announced ...

Over the past six months, Organon’s stock price fell to $7.77. Shareholders have lost 16.1% of their capital, which is ...

(1) Excludes accelerated depreciation included in one-time costs. (2) Spin-related costs reflect certain costs incurred in connection with activities taken to separate Organon from Merck & Co., Inc., ...

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon ...

On this news, the price of Organon stock fell more than 27%. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions ...

SAN DIEGO, July 15, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Organon & Co. (OGN) publicly traded ...